Massive transfusion in trauma: an evolving paradigm.


Journal

Minerva anestesiologica
ISSN: 1827-1596
Titre abrégé: Minerva Anestesiol
Pays: Italy
ID NLM: 0375272

Informations de publication

Date de publication:
Mar 2022
Historique:
pubmed: 13 10 2021
medline: 22 4 2022
entrez: 12 10 2021
Statut: ppublish

Résumé

A considerable amount of literature has nurtured the idea that massive transfusion is an independent trauma disease and therapeutic tool. In this opinion paper, the authors expose the evolution and challenge the classic paradigm and historic definition of massive transfusion. Based on current evidence the elements of an evolving strategy in transfusion management and bleeding control are exposed to use of tranexamic acid, combination and ratios of blood products, use of fluids and viscoelastic testing, etc. The synergy of these elements provides the basis to develop updated strategies and perspectives for transfusion management after trauma and to consider a classic definition of massive transfusion as outdated or the need for massive transfusion as failure. An alternative concept, time critical transfusion may be better placed to take into account modern transfusion management after trauma.

Identifiants

pubmed: 34636221
pii: S0375-9393.21.15914-0
doi: 10.23736/S0375-9393.21.15914-0
doi:

Substances chimiques

Tranexamic Acid 6T84R30KC1

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

184-191

Commentaires et corrections

Type : CommentIn

Auteurs

Tobias Gauss (T)

Unit of Anesthesia and Critical Care, Hôpital Beaujon, DMU PARABOL, APHP Nord - Université de Paris, Paris, France.

Jean-Denis Moyer (JD)

Unit of Anesthesia and Critical Care, Hôpital Beaujon, DMU PARABOL, APHP Nord - Université de Paris, Paris, France.

Pierre Bouzat (P)

Inserm, U1216, Grenoble Institute of Neurosciences, CHU Grenoble Alpes, Grenoble Alpes University, Grenoble, France - PBouzat@chu-grenoble.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH